Esbenshade TA[au] - Search Results

Year	Number of Results
1986	1
1990	1
1992	4
1993	2
1994	3
1995	2
1996	2
1999	1
2001	2
2002	7
2003	11
2004	15
2005	12
2006	12
2007	7
2008	10
2009	5
2010	5
2011	1
2012	1
2013	2
2014	1
2023	0

1

Esbenshade TA, Duzic E. Esbenshade TA, et al. Curr Protoc Pharmacol. 2006 Jan;Chapter 2:Unit2.1. doi: 10.1002/0471141755.ph0201s31. Curr Protoc Pharmacol. 2006. PMID: 21953400 Review.

2

Alpha 1-adrenergic receptor subtypes.

Minneman KP, Esbenshade TA. Minneman KP, et al. Among authors: esbenshade ta. Annu Rev Pharmacol Toxicol. 1994;34:117-33. doi: 10.1146/annurev.pa.34.040194.001001. Annu Rev Pharmacol Toxicol. 1994. PMID: 8042847 Review.

3

Subtypes of alpha-adrenoceptors in contraction of vascular smooth muscle.

Minneman KP, Esbenshade TA, Han C. Minneman KP, et al. Among authors: esbenshade ta. Jpn J Pharmacol. 1992;58 Suppl 2:128P-134P. Jpn J Pharmacol. 1992. PMID: 1324334 Free article. Review. No abstract available.

4

Interactions between co-existing beta-adrenoceptor subtypes in continuous cell lines.

Minneman KP, Esbenshade TA, Zhong H. Minneman KP, et al. Among authors: esbenshade ta. Biochem Soc Trans. 1993 Nov;21(4):1109-14. doi: 10.1042/bst0211109. Biochem Soc Trans. 1993. PMID: 8131909 Review. No abstract available.

5

Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.

Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD. Brioni JD, et al. Among authors: esbenshade ta. J Pharmacol Exp Ther. 2011 Jan;336(1):38-46. doi: 10.1124/jpet.110.166876. Epub 2010 Sep 23. J Pharmacol Exp Ther. 2011. PMID: 20864505 Review.

6

Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.

Esbenshade TA, Fox GB, Cowart MD. Esbenshade TA, et al. Mol Interv. 2006 Apr;6(2):77-88, 59. doi: 10.1124/mi.6.2.5. Mol Interv. 2006. PMID: 16565470 Review.

7

The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. Esbenshade TA, et al. Br J Pharmacol. 2008 Jul;154(6):1166-81. doi: 10.1038/bjp.2008.147. Epub 2008 May 12. Br J Pharmacol. 2008. PMID: 18469850 Free PMC article. Review.

8

Genetic and pharmacological aspects of histamine H3 receptor heterogeneity.

Hancock AA, Esbenshade TA, Krueger KM, Yao BB. Hancock AA, et al. Among authors: esbenshade ta. Life Sci. 2003 Oct 31;73(24):3043-72. doi: 10.1016/j.lfs.2003.06.003. Life Sci. 2003. PMID: 14550847 Review.

9

Histamine H(3) antagonists in models of obesity.

Hancock AA, Bush EN, Jacobson PB, Faghih R, Esbenshade TA. Hancock AA, et al. Among authors: esbenshade ta. Inflamm Res. 2004 Mar;53 Suppl 1:S47-8. doi: 10.1007/s00011-003-0322-5. Epub 2004 Mar 5. Inflamm Res. 2004. PMID: 15054613 No abstract available.

10

The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.

Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR, Krueger KM, Browman KE, Thiffault C, Wetter J, Marsh KC, Hancock AA, Esbenshade TA, Cowart MD. Zhao C, et al. Among authors: esbenshade ta. J Med Chem. 2008 Sep 11;51(17):5423-30. doi: 10.1021/jm8003625. Epub 2008 Aug 7. J Med Chem. 2008. PMID: 18683917

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results